Francesco Marchesi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/647451/publications.pdf

Version: 2024-02-01

124 papers 2,933 citations

279487 23 h-index 205818 48 g-index

126 all docs

126 docs citations

126 times ranked 4657 citing authors

#	Article	IF	CITATIONS
1	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	2.2	430
2	Triazene compounds: Mechanism of action and related DNA repair systems. Pharmacological Research, 2007, 56, 275-287.	3.1	247
3	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189
4	Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. Journal of Hematology and Oncology, 2021, 14, 81.	6.9	149
5	Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplantation, 2015, 50, 282-288.	1.3	142
6	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	2.9	103
7	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews, 2017, 31, 17-29.	2.8	98
8	High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematological Oncology, 2015, 33, 110-112.	0.8	82
9	Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Annals of Hematology, 2018, 97, 1717-1726.	0.8	72
10	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	0.6	70
11	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia, 2022, 36, 1467-1480.	3.3	63
12	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	1.2	56
13	Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematological Oncology, 2018, 36, 381-391.	0.8	50
14	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Advances, 2022, 6, 2427-2433.	2. 5	46
15	Outcome of infection with omicron <scp>SARSâ€CoV</scp> â€2 variant in patients with hematological malignancies: An <scp>EPICOVIDEHA</scp> survey report. American Journal of Hematology, 2022, 97, .	2.0	39
16	High incidence of postâ€transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomibâ€based regimens: a survey from the Rome Transplant Network. Transplant Infectious Disease, 2014, 16, 158-164.	0.7	38
17	Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. Journal of Hematology and Oncology, 2021, 14, 119.	6.9	35
18	A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: Clinical significance of treatment intensity and comprehensive geriatric assessment. Journal of Geriatric Oncology, 2013, 4, 242-248.	0.5	32

#	Article	IF	CITATIONS
19	Biofilm Production by Carbapenem-Resistant Klebsiella pneumoniae Significantly Increases the Risk of Death in Oncological Patients. Frontiers in Cellular and Infection Microbiology, 2020, 10, 561741.	1.8	30
20	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. HemaSphere, 2021, 5, e612.	1.2	29
21	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	2.5	28
22	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplantation, 2017, 52, 154-156.	1.3	27
23	Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. PLoS ONE, 2019, 14, e0224465.	1.1	27
24	Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/ <i>MLL-AF4</i> Positive B-Cell Acute Lymphoblastic Leukemia. Advances in Hematology, 2011, 2011, 1-8.	0.6	26
25	Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. Journal of Experimental and Clinical Cancer Research, 2018, 37, 95.	3.5	25
26	Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. Haematologica, 2019, 104, 82-92.	1.7	24
27	Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: A concise review. Critical Reviews in Oncology/Hematology, 2011, 80, 331-346.	2.0	23
28	Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. Chemotherapy, 2018, 63, 55-63.	0.8	23
29	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. Integrative Cancer Therapies, 2018, 17, 1115-1124.	0.8	23
30	Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas. Leukemia, 2022, 36, 588-590.	3.3	23
31	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. Clinical Infectious Diseases, 2023, 76, e426-e438.	2.9	23
32	Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study. World Journal of Transplantation, 2015, 5, 129.	0.6	22
33	The Impact of Bacterial Biofilms on End-Organ Disease and Mortality in Patients with Hematologic Malignancies Developing a Bloodstream Infection. Microbiology Spectrum, 2021, 9, e0055021.	1.2	21
34	Fungaemia in haematological malignancies: SEIFEMâ€2015 survey. European Journal of Clinical Investigation, 2019, 49, e13083.	1.7	20
35	A bronchoalveolar lavageâ€driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group. American Journal of Hematology, 2019, 94, 1104-1112.	2.0	19
36	Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. DNA Repair, 2007, 6, 1179-1186.	1.3	18

#	Article	IF	CITATIONS
37	Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a singleâ€institution study. Transplant Infectious Disease, 2014, 16, 1032-1038.	0.7	17
38	Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. Journal of Infection, 2016, 72, 265-268.	1.7	17
39	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. Haematologica, 2017, 102, e407-e410.	1.7	17
40	Triazene Compounds in the Treatment of Acute Myeloid Leukemia: A Short Review and a Case Report. Current Medicinal Chemistry, 2013, 20, 2389-2401.	1.2	17
41	Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry. Supportive Care in Cancer, 2016, 24, 3839-3845.	1.0	16
42	Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls. Journal of Experimental and Clinical Cancer Research, 2016, 35, 128.	3.5	16
43	Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant. Chemotherapy, 2017, 62, 58-61.	0.8	15
44	Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?. International Journal of Molecular Sciences, 2019, 20, 1373.	1.8	15
45	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. Journal of Fungi (Basel, Switzerland), 2020, 6, 36.	1.5	15
46	The 12â€week kinetics of antiâ€SARSâ€CoVâ€2 antibodies in different haematological cancers after vaccination with BNT162b2. British Journal of Haematology, 2022, 196, 362-367.	1.2	15
47	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 2023, 108, 22-33.	1.7	15
48	The potential role of preâ€transplant HBclgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. American Journal of Hematology, 2012, 87, 213-217.	2.0	14
49	A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. Annals of Hematology, 2009, 88, 491-493.	0.8	13
50	Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 197-205.	1.3	13
51	Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. British Journal of Haematology, 2021, 193, 316-324.	1.2	12
52	Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic Patients. Infection and Immunity, 2021, 89, e0010521.	1.0	12
53	Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery. Current Medicinal Chemistry, 2016, 23, 2217-2229.	1.2	12
54	Campylobacter jejuni Fatal Sepsis in a Patient with Non-Hodgkin's Lymphoma: Case Report and Literature Review of a Difficult Diagnosis. International Journal of Molecular Sciences, 2016, 17, 544.	1.8	11

#	Article	IF	CITATIONS
55	Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience. British Journal of Haematology, 2016, 172, 980-982.	1.2	11
56	The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network †Rete Ematologica del Lazio per i Linfomi' (RELLI). Leukemia and Lymphoma, 2019, 60, 3386-3394.	0.6	11
57	‬Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 1062-1068.	1.3	11
58	Comparison between biosimilar filgrastim vs other granulocyteâ€colony stimulating factor formulations (originator filgrastim, pegâ€filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. British Journal of Haematology, 2015, 169, 293-296.	1.2	10
59	Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 158-168.	1.3	10
60	Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. Mycoses, 2020, 63, 900-910.	1.8	10
61	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. Chemotherapy, 2021, 66, 47-52.	0.8	10
62	Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells. Blood Cancer Journal, 2020, 10, 85.	2.8	9
63	Biosimilar filgrastim (Zarzio sup \hat{A}^{\otimes} sup) vs. lenograstim (Myelostim sup \hat{A}^{\otimes} sup) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience. Leukemia and Lymphoma, 2016, 57, 489-492.	0.6	8
64	Isavuconazole: Case Report and Pharmacokinetic Considerations. Chemotherapy, 2018, 63, 253-256.	0.8	8
65	Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Supportive Care in Cancer, 2019, 27, 793-803.	1.0	8
66	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Annals of Hematology, 2020, 99, 867-875.	0.8	8
67	Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?. Blood Reviews, 2021, 47, 100776.	2.8	8
68	Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study. HemaSphere, 2019, 3, e320.	1,2	8
69	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Advances, 2022, 6, 3870-3874.	2.5	8
70	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. Blood Cancer Journal, 2022, 12, .	2.8	8
71	Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma. Experimental Hematology and Oncology, 2015, 4, 17.	2.0	7
72	Efficacy and safety of low dose ponatinib in a case of Phâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 187, e15-e17.	1.2	7

#	Article	IF	Citations
73	Factors influencing the perception of protective isolation in patients undergoing haematopoietic stem cell transplantation: A multicentre prospective study. European Journal of Cancer Care, 2019, 28, e13148.	0.7	7
74	The Effect of Docosahexaenoic Acid and \hat{l} ±-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. Integrative Cancer Therapies, 2019, 18, 153473541988858.	0.8	7
75	Development and initial validation of a questionnaire to assess patients' perception of protective isolation following haematopoietic stem cell transplantation. European Journal of Cancer Care, 2019, 28, e12955.	0.7	7
76	Relapse of IgA \hat{l} » Multiple Myeloma Presenting as Obstructive Jaundice and Abdominal Pain. Oncology Research and Treatment, 2009, 32, 119-121.	0.8	6
77	Tuberculous Meningoencephalitis in a Patient with Hairy Cell Leukemia in Complete Remission. Journal of Clinical and Experimental Hematopathology: JCEH, 2012, 52, 31-34.	0.3	6
78	The predictive value of <i>Aspergillus </i> PCR testing on bronchoalveolar lavage fluid for early diagnosis of invasive pulmonary aspergillosis in hematologic patients. Leukemia and Lymphoma, 2017, 58, 2943-2946.	0.6	6
79	BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant. Leukemia and Lymphoma, 2020, 61, 2238-2241.	0.6	6
80	A High-Risk Profile for Invasive Fungal Infections Is Associated with Altered Nasal Microbiota and Niche Determinants. Infection and Immunity, 2022, 90, e0004822.	1.0	6
81	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. Journal of Fungi (Basel,) Tj ETQq1 1 0.7843	l4 rgBT/O	verl o ck 10 T
82	MiRâ€22, a serum predictor of poor outcome and therapy response in diffuse large Bâ€cell lymphoma patients. British Journal of Haematology, 2021, 195, 399-404.	1.2	5
83	Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. Journal of Experimental and Clinical Cancer Research, 2016, 35, 49.	3.5	4
84	Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. Transfusion, 2018, 58, 1143-1148.	0.8	4
85	BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. Bone Marrow Transplantation, 2018, 53, 1051-1054.	1.3	4
86	SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. Expert Review of Hematology, 2018, 11, 155-168.	1.0	4
87	The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 518-527.	1.3	4
88	Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study. Leukemia and Lymphoma, 2020, 61, 3002-3005.	0.6	4
89	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. Critical Reviews in Oncology/Hematology, 2021, 158, 103203.	2.0	4
90	The usefulness of sLORETA in evaluating the effect of high-dose ARA-C on brain connectivity in patients with acute myeloid leukemia: an exploratory study. Functional Neurology, 2017, 32, 195.	1.3	4

#	Article	IF	CITATIONS
91	Infections in Patients with Lymphoproliferative Diseases Treated with Target Therapy. Italian Multicentric Retrospective Study Seifem 2017. Blood, 2018, 132, 4164-4164.	0.6	4
92	A Case of Transplantation-Associated Thrombotic Microangiopathy with Cardiac Involvement Successfully Treated with Plasma Exchange. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 369-371.	0.3	3
93	Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?. Medical Mycology, 2018, 56, 263-278.	0.3	3
94	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1113-1118.	2.0	3
95	Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016â€B survey. Mycoses, 2022, 65, 171-177.	1.8	3
96	Fibrin glue for endoscopic gastrointestinal bleeding in patients with impaired haemostasis. Transfusion Medicine, 2008, 18, 207-208.	0.5	2
97	Patientâ Cr eported outcomes and quality of life assessment: New targets for new targeted therapy?. Cancer, 2016, 122, 1461-1462.	2.0	2
98	Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia. Cognitive Neurodynamics, 2016, 10, 185-188.	2.3	2
99	Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 161-162.	0.2	2
100	Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. Clinical Neuropharmacology, 2019, 42, 167-171.	0.2	2
101	Protection during haempoietic stem cell transplantation: a survey from the quality of life working party of the Rome Transplant Network. BMJ Supportive and Palliative Care, 2019, 9, 110-111.	0.8	2
102	Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020065.	0.5	2
103	Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARSâ€CoVâ€2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT. Transplant Infectious Disease, 2021, , .	0.7	2
104	CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. Leukemia, 2022, , .	3.3	2
105	Sytemic strongyloidiasis and primary aspergillosis of digestive tract in a patient with T-cell acute lymphoblastic leukemia. Leukemia Research, 2011, 35, 978-980.	0.4	1
106	Isavuconazole in Hematological Patients: Results of a Real-Life Multicenter Seifem Study. Blood, 2018, 132, 3710-3710.	0.6	1
107	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. Blood, 2015, 126, 4887-4887.	0.6	1
108	PS1267 ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REALâ€LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY. HemaSphere, 2019, 3, 580-581.	1 _{1.2}	1

#	Article	IF	Citations
109	Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML. Blood, 2019, 134, 1458-1458.	0.6	1
110	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Chemotherapy, 2020, 65, 35-41.	0.8	1
111	Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin. Blood, 2021, 138, 4381-4381.	0.6	1
112	COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A) Tj ETQq0	0 0. 6gBT /	'O v erlock 10
113	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. Blood, 2020, 136, 32-33.	0.6	1
114	In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia. Journal of Clinical Medicine, 2022, 11, 1776.	1.0	1
115	Rehabilitation need and referrals in hematopoietic stem cell transplantation: the experience of Quality of Life Working Party of the Rome Transplant Network. Bone Marrow Transplantation, 2016, 51, 638-639.	1.3	0
116	Gender, age and diagnosis effect on self-perceived pain in hematological patients: retrospective analysis of two case series. Annals of Palliative Medicine, 2018, 7, 484-486.	0.5	0
117	Hematologic Issues in Cervical Spine Surgery. , 2010, , 13-27.		0
118	Survival of Patients with High Risk Hematological Malignancy after Allogeneic Transplant from HLA Identical Siblings Is Comparable to That of Patients Transplanted from Haploidentical, Unmanipulated Bone Marrow Donor: Results of a Matched-Pair Analysis from the Rome Transplant Network. Blood, 2014, 124, 1223-1223.	0.6	0
119	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. Blood, 2015, 126, 1023-1023.	0.6	0
120	Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia. Blood, 2015, 126, 2004-2004.	0.6	0
121	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study. Blood, 2016, 128, 3700-3700.	0.6	0
122	S1637 A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP. HemaSphere, 2019, 3, 756-757.	1.2	0
123	lgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. Blood, 2020, 136, 30-31.	0.6	0
124	When Viruses Meet Fungi: Tackling the Enemies in Hematology. Journal of Fungi (Basel, Switzerland), 2022, 8, 184.	1.5	0